Occult hepatitis B infection in chronic hemodialysis patients: Current concepts and strategy

F. Blaine Hollinger, Peiman Habibollahi, Ali Daneshmand, Seyed Moayed Alavian

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

The prevalence of end-stage renal disease has increased dramatically in developing countries, and this has been accompanied by the widespread utilization of chronic hemodialysis in its management prior to kidney transplantation. Within this group, the interjection of hepatitis B virus (HBV) infection represents a significant co-morbidity event that has led to several outbreaks of hepatitis B. Occult hepatitis B (OHB) is a variant of conventional hepatitis B that is manifested by the presence of HBV DNA in blood and/or tissue in the absence of hepatitis B surface antigen (HBsAg). It is postulated that its impact on chronic hemodialysis patients also might be of importance. Unfortunately, there are only a limited number of published studies on this topic and, in most cases, only prevalence data are reported without descriptions of histopathology or outcome measurements. In this paper, we have reviewed this information. Based on the scarcity of available data, HBV DNA assessment with highly sensitive assays might be informative in this target population, especially among those hemodialysis patients who present with isolated antibodies to the hepatitis B core antigen (anti-HBc) or who are hepatitis C virus (HCV) RNA positive, since HCV coinfection appears to worsen the outcome. Clearly, more precise studies need to be performed to answer questions concerning the impact of OHB in chronic hemodialysis patients.

Original languageEnglish (US)
Pages (from-to)199-204
Number of pages6
JournalHepatitis Monthly
Volume10
Issue number3
StatePublished - Jul 29 2010
Externally publishedYes

Fingerprint

Hepatitis B
Renal Dialysis
Hepatitis B virus
Infection
Hepacivirus
Hepatitis B Core Antigens
Health Services Needs and Demand
DNA
Chronic Hepatitis B
Virus Diseases
Hepatitis B Surface Antigens
Coinfection
Kidney Transplantation
Developing Countries
Chronic Kidney Failure
Disease Outbreaks
RNA
Morbidity
Antibodies

Keywords

  • HBV
  • Hemodialysis
  • Occult hepatitis B

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Occult hepatitis B infection in chronic hemodialysis patients : Current concepts and strategy. / Hollinger, F. Blaine; Habibollahi, Peiman; Daneshmand, Ali; Alavian, Seyed Moayed.

In: Hepatitis Monthly, Vol. 10, No. 3, 29.07.2010, p. 199-204.

Research output: Contribution to journalReview article

Hollinger, F. Blaine ; Habibollahi, Peiman ; Daneshmand, Ali ; Alavian, Seyed Moayed. / Occult hepatitis B infection in chronic hemodialysis patients : Current concepts and strategy. In: Hepatitis Monthly. 2010 ; Vol. 10, No. 3. pp. 199-204.
@article{4ebb973e4644434197d0ae94605ae236,
title = "Occult hepatitis B infection in chronic hemodialysis patients: Current concepts and strategy",
abstract = "The prevalence of end-stage renal disease has increased dramatically in developing countries, and this has been accompanied by the widespread utilization of chronic hemodialysis in its management prior to kidney transplantation. Within this group, the interjection of hepatitis B virus (HBV) infection represents a significant co-morbidity event that has led to several outbreaks of hepatitis B. Occult hepatitis B (OHB) is a variant of conventional hepatitis B that is manifested by the presence of HBV DNA in blood and/or tissue in the absence of hepatitis B surface antigen (HBsAg). It is postulated that its impact on chronic hemodialysis patients also might be of importance. Unfortunately, there are only a limited number of published studies on this topic and, in most cases, only prevalence data are reported without descriptions of histopathology or outcome measurements. In this paper, we have reviewed this information. Based on the scarcity of available data, HBV DNA assessment with highly sensitive assays might be informative in this target population, especially among those hemodialysis patients who present with isolated antibodies to the hepatitis B core antigen (anti-HBc) or who are hepatitis C virus (HCV) RNA positive, since HCV coinfection appears to worsen the outcome. Clearly, more precise studies need to be performed to answer questions concerning the impact of OHB in chronic hemodialysis patients.",
keywords = "HBV, Hemodialysis, Occult hepatitis B",
author = "Hollinger, {F. Blaine} and Peiman Habibollahi and Ali Daneshmand and Alavian, {Seyed Moayed}",
year = "2010",
month = "7",
day = "29",
language = "English (US)",
volume = "10",
pages = "199--204",
journal = "Hepatitis Monthly",
issn = "1735-143X",
publisher = "Kowsar Publishing Company",
number = "3",

}

TY - JOUR

T1 - Occult hepatitis B infection in chronic hemodialysis patients

T2 - Current concepts and strategy

AU - Hollinger, F. Blaine

AU - Habibollahi, Peiman

AU - Daneshmand, Ali

AU - Alavian, Seyed Moayed

PY - 2010/7/29

Y1 - 2010/7/29

N2 - The prevalence of end-stage renal disease has increased dramatically in developing countries, and this has been accompanied by the widespread utilization of chronic hemodialysis in its management prior to kidney transplantation. Within this group, the interjection of hepatitis B virus (HBV) infection represents a significant co-morbidity event that has led to several outbreaks of hepatitis B. Occult hepatitis B (OHB) is a variant of conventional hepatitis B that is manifested by the presence of HBV DNA in blood and/or tissue in the absence of hepatitis B surface antigen (HBsAg). It is postulated that its impact on chronic hemodialysis patients also might be of importance. Unfortunately, there are only a limited number of published studies on this topic and, in most cases, only prevalence data are reported without descriptions of histopathology or outcome measurements. In this paper, we have reviewed this information. Based on the scarcity of available data, HBV DNA assessment with highly sensitive assays might be informative in this target population, especially among those hemodialysis patients who present with isolated antibodies to the hepatitis B core antigen (anti-HBc) or who are hepatitis C virus (HCV) RNA positive, since HCV coinfection appears to worsen the outcome. Clearly, more precise studies need to be performed to answer questions concerning the impact of OHB in chronic hemodialysis patients.

AB - The prevalence of end-stage renal disease has increased dramatically in developing countries, and this has been accompanied by the widespread utilization of chronic hemodialysis in its management prior to kidney transplantation. Within this group, the interjection of hepatitis B virus (HBV) infection represents a significant co-morbidity event that has led to several outbreaks of hepatitis B. Occult hepatitis B (OHB) is a variant of conventional hepatitis B that is manifested by the presence of HBV DNA in blood and/or tissue in the absence of hepatitis B surface antigen (HBsAg). It is postulated that its impact on chronic hemodialysis patients also might be of importance. Unfortunately, there are only a limited number of published studies on this topic and, in most cases, only prevalence data are reported without descriptions of histopathology or outcome measurements. In this paper, we have reviewed this information. Based on the scarcity of available data, HBV DNA assessment with highly sensitive assays might be informative in this target population, especially among those hemodialysis patients who present with isolated antibodies to the hepatitis B core antigen (anti-HBc) or who are hepatitis C virus (HCV) RNA positive, since HCV coinfection appears to worsen the outcome. Clearly, more precise studies need to be performed to answer questions concerning the impact of OHB in chronic hemodialysis patients.

KW - HBV

KW - Hemodialysis

KW - Occult hepatitis B

UR - http://www.scopus.com/inward/record.url?scp=77954875607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954875607&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:77954875607

VL - 10

SP - 199

EP - 204

JO - Hepatitis Monthly

JF - Hepatitis Monthly

SN - 1735-143X

IS - 3

ER -